Please assess the completion status of the following clinical trial:

Trial Title: Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (age 21-75 inclusive) men and women of non child bearing potential with established or symptomatic gout which is defined as having at least ONE of any of the 3 following factors:~   1. ≥ 1 tophus~  2. 1 gout flare within the last 6 months~  3. Chronic gouty arthropathy~2. Screening serum uric acid of \>6 mg/dL~3. On a gout flare prophylactic regimen for 7 days prior to first dose~4. Willing to provide written informed consent prior to first study procedure is performed.~5. Understands and is willing and able to comply with study requirements, including the schedule of follow-up visits.~Exclusion Criteria:~1. History of anaphylaxis or severe allergic reaction.~2. History of an allergy to pegylated products.~3. Women of child bearing potential, Defined as:~   * \<6 weeks after surgical bilateral salpingooperhectony with or without hysterectomy~  * Pre or perimenopausal ( \< less than 24 months of natural amenorrhea)~4. Initiation or change in dose of hormone-replacement therapy for menopausal women less than 1 month prior to the Screening Visit or during the Screening Phase would be exclusionary. If after being on a stable dose of hormone-replacement therapy for one month the patient may be considered for the study if she continues to meet all other inclusion and exclusion criteria~5. Uncontrolled diabetes with baseline HbA1c ≥8%;~6. Glucose-6-phosphate dehydrogenase deficiency;~7. Uncontrolled hypertension~8. Ongoing treatment for arrhythmia, including placement of an implantable defibrillator;~9. History of coronary artery disease, including myocardial infarction;~10. Congestive heart failure, New York Heart Association Class III or IV;~11. ECG with evidence of prior myocardial infarction, clinically significant arrhythmia, or other abnormalities that, in the opinion of the investigator, are consistent with significant underlying cardiac disease;~12. History of hematological or autoimmune disorders, is immunosuppressed or immunocompromised;~13. Prior exposure to any experimental or marketed uricase (e.g., rasburicase (Elitek, Fasturtec), pegloticase (Krystexxa®), pegsiticase (SEL-037)~14. History of malignancy within the last 5 years other than basal skin cancer;~15. Subjects who, in the opinion of the investigator, present with a condition that would compromise their safety or that would make study completion unlikely.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SEL-037 Pegadricase LD (low dose) alone (Type: EXPERIMENTAL): Pegadricase 0.2 mg/kg intravenous (IV) every 28 days for 5 treatments
- SEL-037 Pegadricase HD (high dose) alone (Type: EXPERIMENTAL): Pegadricase 0.4 mg/kg intravenous (IV) every 28 days for 5 treatments
- SEL-212, Pegadricase LD & SEL-110 (1a) (Type: EXPERIMENTAL): Pegadricase 0.2 mg/kg IV plus SEL-110 0.05 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
- SEL-212, Pegadricase HD & SEL-110 (1b) (Type: EXPERIMENTAL): Pegadricase 0.4 mg/kg IV plus SEL-110 0.05 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
- SEL-212, Pegadricase LD & SEL-110 (2a) (Type: EXPERIMENTAL): Pegadricase 0.2 mg/kg IV plus SEL-110 0.08 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
- SEL-212, Pegadricase HD & SEL-110 (2b) (Type: EXPERIMENTAL): Pegadricase 0.4 mg/kg IV plus SEL-110 0.08 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
- SEL-212, Pegadricase HD & SEL-110 (3a) (Type: EXPERIMENTAL): Pegadricase 0.2 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
- SEL-212, Pegadricase HD & SEL-110 (3b) (Type: EXPERIMENTAL): Pegadricase 0.4 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
- SEL-212, Pegadricase HD & SEL-110 (4a) (Type: EXPERIMENTAL): Pegadricase 0.4 mg/kg IV plus SEL-110 0.125 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
- SEL-212, Pegadricase HD & SEL-110 (4b) (Type: EXPERIMENTAL): Pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments
- SEL-212, Pegadricase HD & SEL-110 (5a) (Type: EXPERIMENTAL): Pegadricase 0.4 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments
- SEL-212, Pegadricase HD & SEL-110 (5b) (Type: EXPERIMENTAL): Pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 5 treatments
- SEL-212, Pegadricase HD & SEL-110 (6a) (Type: EXPERIMENTAL): Pegadricase 0.2 mg/kg IV plus SEL-110 0.10 mg/kg IV every 28 days for 1 treatment followed by pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 4 treatments
- SEL-212, Pegadricase HD & SEL-110 (6b) (Type: EXPERIMENTAL): Pegadricase 0.2 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 5 treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).